The association of beta-blocker use with mortality in elderly patients with congestive heart failure and advanced chronic kidney disease.

ABSTRACT: BACKGROUND:Whether the survival benefit of β-blockers in congestive heart failure (CHF) from randomized trials extends to patients with advanced chronic kidney disease (CKD) [estimated glomerular filtration rate (eGFR) <30 mL/min/1.73 m2 but not receiving dialysis] is uncertain. METHODS:This was a retrospective cohort study using administrative datasets. Older adults from Ontario, Canada, with incident CHF (median age 79 years) from April 2002 to March 2014 were included. We matched new users of β-blockers to nonusers on age, sex, eGFR categories (>60, 30-60, <30), CHF diagnosis date and a high-dimensional propensity score. Using Cox proportional hazards models, we examined the association of β-blocker use versus nonuse with all-cause mortality. RESULTS:We matched 5862 incident β-blocker u

SUBMITTER: Molnar AO 

PROVIDER: S-EPMC7203558 | biostudies-literature | 2020 May

REPOSITORIES: biostudies-literature